Vice President, Clinical Pharmacology

Ming Lu, Ph.D., serves as Vice President, Clinical Pharmacology for Avenzo Therapeutics. Dr. Lu has more than 20 years of biotechnology development experience, most recently serving as Vice President, Clinical Pharmacology, at Bristol Myers Squibb following its acquisition of Turning Point Therapeutics in August 2022. At Turning Point Therapeutics/BMS, he led the clinical pharmacology function to support the global development of the clinical stage pipeline, including the NDA submission of AUGTYRO™ (repotrectinib).

Prior to Turning Point Therapeutics, Dr. Lu had extensive experience in leading clinical pharmacology/early development at Ascentage Pharma, Johnson & Johnson, and Bayer, and played vital roles in the regulatory approvals of olverembatinib, STELARA® and SIMPONI®.

Dr. Lu received his Ph.D. in Pharmaceutical Sciences from University of Kentucky, and a Master of Medicine and B.S. in Pharmacy from Zhejiang University in China.